Last updated: August 27, 2026
Ornidyl is the former brand name for intravenous eflornithine hydrochloride, an antitrypanosomal drug used against late-stage human African trypanosomiasis, or sleeping sickness. Its commercial profile differs sharply from conventional pharmaceutical products: demand is determined by disease-elimination programs, procurement agencies and donations rather than retail prescriptions. Standalone sales and profitability are not publicly reported. The product’s economic value has therefore been measured primarily through public-health access, manufacturing continuity and its role in combination therapy.
What is Ornidyl and how is eflornithine used?
Ornidyl contains eflornithine hydrochloride for intravenous treatment of second-stage infection caused by Trypanosoma brucei gambiense. The disease has central nervous system involvement at this stage and requires treatment capable of crossing into the brain.
The original FDA indication covered late-stage sleeping sickness caused by T. b. gambiense. Eflornithine is administered intravenously over multiple days, creating a substantial logistical burden compared with oral treatments. The regimen also requires trained personnel, infusion equipment and reliable hospital or treatment-center infrastructure.
Eflornithine later became a component of nifurtimox-eflornithine combination therapy, known as NECT. NECT combines intravenous eflornithine with oral nifurtimox and has been recommended for eligible second-stage T. b. gambiense cases because it reduces the duration and infusion burden associated with eflornithine monotherapy.[1]
The same active ingredient is used in topical eflornithine products for unwanted facial hair, including Vaniqa. Those products are commercially distinct from Ornidyl and should not be included in the antitrypanosomal market calculation.
When did Ornidyl lose exclusivity and what is its Orange Book status?
Ornidyl’s commercial exclusivity expired many years ago. The drug was approved in the United States in 1990, and any original small-molecule patent protection would have expired well before the current period.[2]
| Item |
Ornidyl status |
| Active ingredient |
Eflornithine hydrochloride |
| Route |
Intravenous |
| Original indication |
Late-stage T. b. gambiense sleeping sickness |
| U.S. approval |
1990 |
| Regulatory category |
Small-molecule prescription drug |
| Patent position |
Original exclusivity expired |
| Current commercial profile |
Limited or non-retail, program-driven supply |
| Biosimilar exposure |
None; eflornithine is a small molecule |
| Generic exposure |
Technically possible, commercially limited by market size |
| Orange Book relevance |
Limited because the product is not a conventional high-volume retail franchise |
The FDA Orange Book remains relevant for determining listed patents and marketing status, but Ornidyl does not have the type of active, high-value Orange Book estate associated with major chronic-care drugs. The economic barriers to competition are more likely to involve sterile manufacturing, procurement qualification, regulatory maintenance and low-volume economics than patent claims.[2]
No material current patent barrier is generally associated with the original eflornithine injection product. Formulation, manufacturing and combination-product patents would need to be reviewed separately for any specific supplier or presentation. The original Ornidyl franchise should not be treated as patent-protected based on its historic brand identity.
What is the FDA regulatory status of Ornidyl?
Ornidyl was approved by the FDA for severe sleeping sickness, but the U.S. market has never represented the principal demand center. Human African trypanosomiasis is concentrated in sub-Saharan Africa, and treatment access is coordinated through national programs, the World Health Organization and international procurement channels.
The relevant regulatory distinction is between:
- The historic U.S. approval of intravenous eflornithine.
- WHO-recommended use of eflornithine, particularly in NECT.
- Country-level registration, importation and procurement arrangements in endemic markets.
- Topical eflornithine products, which have a different indication and commercial market.
The FDA approval does not create a broad commercial market. Sleeping sickness has a very small patient population relative to mainstream infectious diseases, and most treated patients are outside the United States.
How large is the Ornidyl market?
The market is small in commercial terms but strategically important in public health. Disease incidence has fallen substantially over the past two decades. WHO reported fewer than 1,000 detected human African trypanosomiasis cases globally in recent years, compared with tens of thousands annually in earlier periods.[3]
The decline in cases has two opposing effects:
- It reduces the quantity of eflornithine required for treatment.
- It increases the risk that manufacturers will exit because fixed production, quality-control and regulatory costs are spread across fewer units.
The addressable market is therefore determined by treated cases rather than by the much larger population living in endemic areas. Screening populations may remain large, but confirmed treatment demand is low.
Market drivers
| Driver |
Effect on eflornithine demand |
| Declining sleeping-sickness incidence |
Reduces unit demand |
| WHO elimination programs |
Sustains procurement and access |
| NECT adoption |
Preserves eflornithine’s clinical role |
| Oral fexinidazole availability |
Reduces demand in eligible patients |
| Drug-donation agreements |
Suppress commercial pricing |
| Low-volume sterile manufacturing |
Raises supply risk |
| Geographic concentration in Africa |
Limits retail commercialization |
| Outbreak or cluster activity |
Can create episodic procurement increases |
Fexinidazole has changed the competitive environment. It is an oral treatment for eligible patients with T. b. gambiense infection and can reduce dependence on intravenous regimens. The WHO has incorporated fexinidazole into treatment guidance for appropriate stages and patient groups, while NECT remains important where fexinidazole is unsuitable or unavailable.[1]
How does Ornidyl compare with fexinidazole, pentamidine and melarsoprol?
Eflornithine is not competing in a normal branded-drug category. Its relevant competitors are treatment regimens selected by parasite subspecies, disease stage, patient characteristics, supply conditions and national protocols.
| Treatment |
Main role |
Administration |
Commercial effect on eflornithine |
| Eflornithine monotherapy |
Historic treatment for late-stage T. b. gambiense |
Intravenous, intensive regimen |
Demand has declined as NECT became preferred |
| NECT |
Eflornithine plus nifurtimox for eligible late-stage T. b. gambiense cases |
Intravenous plus oral |
Preserves eflornithine demand while reducing infusion burden |
| Fexinidazole |
Oral treatment for eligible T. b. gambiense cases |
Oral |
Directly reduces injectable eflornithine use |
| Pentamidine |
Earlier-stage T. b. gambiense |
Injection |
Not a direct substitute for late-stage eflornithine |
| Melarsoprol |
Severe disease, especially some T. b. rhodesiense settings |
Intravenous |
Toxicity limits use but retains a role in selected cases |
| Suramin |
Earlier-stage T. b. rhodesiense |
Intravenous |
Addresses a different clinical segment |
Fexinidazole is the most important modern demand substitute for eflornithine in eligible gambiense cases. NECT remains relevant because it has strong clinical experience, broad programmatic use and a role when oral treatment is inappropriate.
What companies supply or support Ornidyl and eflornithine?
Sanofi has historically been the central industrial partner associated with eflornithine access. The company supported donation and supply arrangements for sleeping-sickness treatment in collaboration with WHO and other partners. Sanofi’s role has included eflornithine and related antitrypanosomal medicines in access programs rather than conventional commercial promotion.[4]
The supply chain also involves:
- WHO, which coordinates treatment guidance, procurement and distribution support.
- National disease-control programs.
- International donors and procurement organizations.
- Qualified manufacturers of active pharmaceutical ingredient and sterile injectable product.
- Research and development groups, including DNDi, which helped advance improved sleeping-sickness treatment options such as NECT and fexinidazole.[5]
The key commercial question is not which company can charge the highest price. It is whether a qualified supplier will maintain production at volumes sufficient for sporadic demand while meeting sterile-injectable quality requirements.
What is the financial trajectory for Ornidyl?
No public company reporting provides a reliable standalone revenue series for Ornidyl or antitrypanosomal eflornithine. Sanofi’s financial reports aggregate products into broad business segments and do not disclose separate Ornidyl revenue, gross margin, operating profit or unit volumes.[6]
The financial trajectory can nevertheless be characterized:
1. Original commercial phase
After FDA approval, eflornithine had a conventional branded-drug profile in regulatory terms. The market was always narrow because sleeping sickness is geographically concentrated and clinically uncommon in developed markets.
2. Access-program phase
The product shifted toward donation and public-health procurement. Revenue economics became less important than maintaining affordable access and stable supply. This reduced the relevance of retail price, sales-force investment and brand competition.
3. Combination-therapy phase
NECT preserved demand for eflornithine but changed its use from monotherapy to a co-administered regimen. Unit demand per patient and treatment logistics changed, while the drug retained a place in the WHO treatment architecture.[1]
4. Elimination phase
As case numbers declined and fexinidazole expanded the oral-treatment pathway, total eflornithine demand likely contracted. At the same time, the strategic cost of supply interruption increased because fewer manufacturers may remain willing to support the product.
| Financial variable |
Direction |
| Unit volume |
Down over the long term |
| Retail sales |
Minimal relative to major pharmaceutical products |
| Public-health procurement |
More important than commercial sales |
| Pricing power |
Low |
| Manufacturing cost per unit |
Potentially high because of low scale |
| Gross-margin visibility |
Not publicly disclosed |
| Patent-driven value |
Negligible |
| Supply-continuity value |
High relative to direct revenue |
| Long-term growth potential |
Limited |
The product is best viewed as a low-revenue, low-growth, access-critical medicine rather than as a scalable pharmaceutical franchise.
What manufacturing and intellectual-property barriers affect eflornithine?
The primary barriers are operational rather than patent-based.
Sterile injectable production
Eflornithine injection requires sterile manufacturing, validated filling processes, quality testing and compliant packaging. Low annual volumes make fixed costs material. A manufacturer must preserve capacity even when orders are irregular.
Active pharmaceutical ingredient supply
API availability can be a constraint if only a small number of qualified producers operate at commercial scale. Long procurement cycles and limited inventory can increase the risk of temporary shortages.
Regulatory maintenance
The supplier must maintain product registrations, pharmacovigilance systems, manufacturing authorizations and quality documentation across relevant jurisdictions. Those activities generate recurring costs despite low sales.
Regimen integration
Eflornithine is increasingly supplied as part of a treatment system involving nifurtimox, diagnostic staging and clinical protocols. A supplier that cannot coordinate with procurement programs may lose practical market access even without facing patent competition.
Intellectual property
The original eflornithine composition and use patents are no longer a meaningful barrier. Potentially relevant rights could include:
- Improved formulations.
- Injectable presentations.
- Combination regimens.
- Manufacturing processes.
- Packaging or stability technologies.
- New uses in parasitic disease.
Those rights would need claim-by-claim review and jurisdiction-specific status analysis. They do not restore exclusivity to the historic Ornidyl product.
Which companies are challenging Ornidyl exclusivity?
No major Paragraph IV campaign is associated with Ornidyl comparable to the litigation surrounding high-revenue U.S. branded medicines. The reason is economic: the product has limited U.S. demand, no meaningful remaining patent franchise and a small global treatment market.
A generic entrant could theoretically seek approval or market authorization for eflornithine injection. The commercial case is weak because:
- Patient volumes are low.
- Purchases are concentrated in tenders and public-health programs.
- Donation pricing limits upside.
- Sterile manufacturing costs are high.
- Procurement qualification can be lengthy.
- Demand may fall as oral fexinidazole use expands.
Generic entry would therefore be more likely to improve supply resilience than to generate substantial pharmaceutical revenue.
What litigation and settlement agreements affect Ornidyl?
There is no widely reported current patent litigation or settlement agreement that materially affects the antitrypanosomal eflornithine market. Historic legal disputes involving eflornithine-related products should be separated from the sleeping-sickness product because topical eflornithine for facial hair has a different indication, formulation, commercial market and patent history.
For Ornidyl, the more relevant legal instruments are likely to be:
- Donation agreements.
- Government procurement contracts.
- Quality and supply agreements.
- Technology-transfer arrangements.
- Country-level registration and importation permissions.
These agreements can influence access and continuity without creating conventional market exclusivity.
What generic launch risks exist for Ornidyl?
A generic launch would face low patent risk but high commercial execution risk.
| Risk |
Assessment |
| Patent challenge |
Low |
| FDA regulatory pathway |
Technically available, commercially unattractive |
| U.S. demand |
Very limited |
| Endemic-market demand |
Program-driven and fragmented |
| Sterile manufacturing |
Significant barrier |
| Procurement qualification |
Significant barrier |
| Pricing environment |
Low-price or donation-oriented |
| Competitive response |
Limited branded response |
| Supply interruption risk |
Meaningful |
| Investment return |
Likely modest |
A new entrant would need a procurement strategy rather than a conventional retail-launch plan. The best commercial rationale would be institutional contracts, public-health tenders and supply-continuity commitments.
How strong is the Ornidyl patent estate?
The historic patent estate is weak as a current commercial asset. Eflornithine is an old small molecule, and the original product approval dates to 1990. Patent expiration has removed the principal mechanism for market exclusivity.
The broader IP position is more nuanced:
- Product-level exclusivity is effectively exhausted.
- New formulation claims may have limited scope and value.
- Combination-treatment claims may protect a regimen rather than standalone eflornithine.
- Manufacturing claims could create practical advantages but are unlikely to support premium pricing.
- Regulatory and procurement relationships may be more valuable than patents.
On a commercial basis, the estate should be rated low for exclusivity, moderate for supply-chain defensibility and high for public-health relevance.
What generic launch scenarios are plausible?
Scenario 1: Continued incumbent or donor-supported supply
This is the most likely structure where a qualified supplier continues to support WHO-linked procurement. Prices remain controlled, and the product remains available for patients who need NECT or cannot receive oral alternatives.
Scenario 2: Specialist generic entry
A generic manufacturer enters to supply endemic-country tenders. The entrant gains limited revenue but improves redundancy in the supply base. This scenario depends on procurement commitments.
Scenario 3: Further demand substitution
Fexinidazole expands among eligible patients, reducing eflornithine use. Eflornithine remains necessary for defined clinical populations and in settings where oral therapy is unsuitable or unavailable.
Scenario 4: Supply-constrained market
Manufacturers reduce production because of weak economics. Even with no patent barriers, procurement agencies face shortages or longer lead times. In this scenario, the value of manufacturing access exceeds the value of brand ownership.
What is the geographic coverage of the Ornidyl market?
The commercial center of gravity is sub-Saharan Africa. Countries with historical or ongoing sleeping-sickness programs include the Democratic Republic of the Congo, Central African Republic, Guinea, South Sudan, Chad, Côte d’Ivoire, Uganda and other endemic states.
The Democratic Republic of the Congo has historically accounted for a large share of reported gambiense cases. Geographic demand is affected by conflict, surveillance capacity, rural access, diagnostic infrastructure and cross-border transmission. A decline in reported cases does not eliminate the need for treatment inventory because disease detection and access remain uneven.[3]
The United States and Europe are primarily regulatory, donor or specialist-treatment markets rather than volume markets. Any revenue forecast based on U.S. prescriptions would materially overstate the product’s global economic importance.
Key Takeaways
- Ornidyl is intravenous eflornithine hydrochloride for late-stage gambiense sleeping sickness.
- Its original U.S. approval dates to 1990, and meaningful product-level patent exclusivity has expired.
- Standalone revenue, profit and unit-volume data are not publicly reported.
- The product is driven by WHO programs, public procurement and donations, not retail demand.
- NECT preserves eflornithine’s clinical role, while fexinidazole creates demand pressure through oral substitution.
- The main barriers are sterile manufacturing, low volumes, procurement qualification and supply continuity.
- Generic entry is legally feasible but commercially difficult.
- The asset has low patent value, low conventional revenue potential and high public-health importance.
- Financial performance should be assessed through supply contracts, manufacturing economics and program funding rather than brand sales.
FAQs
Is Ornidyl still commercially available?
Eflornithine remains relevant to sleeping-sickness treatment programs, particularly through NECT, but availability is primarily organized through public-health procurement rather than ordinary retail distribution.
Is Ornidyl the same as Vaniqa?
No. Both products contain eflornithine, but Ornidyl is an intravenous antitrypanosomal product and Vaniqa is a topical product for unwanted facial hair.
Does Ornidyl have biosimilar competition?
No. Eflornithine is a small molecule, so the relevant competitive pathway is generic drug competition, not biosimilar substitution.
Can fexinidazole replace eflornithine in all patients?
No. Fexinidazole is available only for eligible patients and specific clinical settings. Eflornithine-based treatment remains relevant where oral therapy is unsuitable, unavailable or not recommended.
Is Ornidyl an attractive licensing asset?
As a standalone branded product, it has limited licensing value. Its stronger strategic value lies in manufacturing rights, public-health supply agreements, procurement access and the ability to provide a reliable source of injectable eflornithine.
References
-
World Health Organization. (2024). WHO guidelines for the treatment of human African trypanosomiasis. World Health Organization.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
World Health Organization. (2023). Human African trypanosomiasis: Number of cases. World Health Organization. https://www.who.int/data/gho/data/themes/topics/human-african-trypanosomiasis
-
World Health Organization. (n.d.). Human African trypanosomiasis: Access to treatment and medicines. World Health Organization.
-
Drugs for Neglected Diseases initiative. (n.d.). Human African trypanosomiasis. https://dndi.org/diseases/human-african-trypanosomiasis/
-
Sanofi. (2024). Universal registration document and annual financial report 2023. Sanofi.
